🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

1,187 results for “Takeda” Clear

  1. Veltuzumab

    Takeda

    Rheumatoid Arthritis

    phase 2 small molecule terminated

    1 trial

  2. Vidaza 25 mg/ml powder for suspension for injection, Azacitidin STADA 25 mg/ml Pulver zur Herstellung einer Injektionssuspension, Venclyxto 10 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Azacitidine Mylan 25 mg/mL powder for suspension for injection, Azacitidine Mylan 25 mg/mL powder for suspension for injection, pevonedistat hydrochloride, Venclyxto 100 mg film-coated tablets

    Takeda

    Acute Myeloid Leukemia

    phase 2 small molecule active

    1 trial

  3. Vonoprazan

    Takeda

    Gastroesophageal Reflux

    phase 2 small molecule completed

    1 trial

  4. Vortioxetine

    Takeda

    Binge Eating Disorder

    phase 2 small molecule completed

    1 trial

  5. Vortioxetine (IV)

    Takeda

    Depressive Disorder, Major

    phase 2 small molecule completed

    1 trial

  6. ZASOCITINIB

    Takeda

    Moderate to Severely Active Ulcerative Colitis & Moderate to Severely Active Crohn's Disease

    phase 2 small molecule active

    1 trial

  7. ZASOCITINIB, Matching Placebo for TAK-279

    Takeda

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  8. ZASOCITINIB, ZASOCITINIB, White opaque, hard hypromellose capsule, size 3 containing same excipients as TAK-279 active capsule

    Takeda

    Non-segmental vitiligo

    phase 2 small molecule active

    1 trial

  9. ZED1227 + SIGE

    Takeda

    Celiac Disease

    phase 2 small molecule active

    1 trial

  10. Zasocitinib

    Takeda

    Nonsegmental Vitiligo

    phase 2 small molecule active

    1 trial

  11. Zasocitinib

    Takeda

    Crohn's Disease

    phase 2 small molecule active

    2 trials

  12. Zasocitinib (Dose A)

    Takeda

    Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  13. alisertib

    Takeda

    Malignant Rhabdoid Tumor

    phase 2 small molecule active

    1 trial

  14. anagrelide hydrochloride

    Takeda

    Essential Thrombocythaemia

    phase 2 small molecule completed

    1 trial

  15. budesonide

    Takeda

    Eosinophilic Esophagitis (EoE)

    phase 2 small molecule completed

    1 trial

  16. ecallantide 60 mg

    Takeda

    ACE Inhibitor Induced Angioedema

    phase 2 small molecule terminated

    1 trial

  17. elritercept

    Takeda

    Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS).

    phase 2 small molecule active

    1 trial

  18. fruquintinib

    Takeda

    Colon Cancer

    phase 2 small molecule active

    1 trial

  19. lanadelumab

    Takeda

    COVID-19

    phase 2 mab completed

    1 trial

  20. lisdexamfetamine dimesylate (SPD489)

    Takeda

    Binge Eating Disorder

    phase 2 small molecule completed

    1 trial

  21. metformin

    Takeda

    Type 2 Diabetes

    phase 2 small molecule completed

    1 trial

  22. oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab

    Takeda

    Colorectal Carcinoma

    phase 2 small molecule completed

    1 trial

  23. peginesatide

    Takeda

    Anemia

    phase 2 small molecule completed

    5 trials

  24. pioglitazone

    Takeda

    Alzheimer Disease

    phase 2 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources